Skip to main content
SGMT
NASDAQ Life Sciences

FDA Greenlights Phase 3 Trial of Denifanstat for Moderate to Severe Acne

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$9.48
Mkt Cap
$574.521M
52W Low
$4.5
52W High
$10.062
52W Position info
111% above low
Off High info
5.8% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

SGMT has more than doubled off its 52-week low of $4.5.

Summary

The FDA cleared Sagimet's IND for denifanstat in moderate to severe acne, allowing the Phase 3 trial to proceed—a key step in the company's pivot to dermatology.


Key Events · Product Development and Regulatory · SGMT

  • FDA Clears Phase 3 Acne Trial

    The FDA issued a 'Study May Proceed' letter for denifanstat in moderate to severe acne, clearing the IND application.

  • Strategic Pivot to Dermatology

    This milestone advances Sagimet's pivot toward acne, with a U.S. Phase 3 trial planned for H2 2026.

  • Cash Runway Supports Development

    As of Q2 2026, the company reported $257.6 million in cash, sufficient to fund the Phase 3 program.

  • Next Milestone: Trial Initiation

    Phase 3 trial initiation is expected in H2 2026, with data readout likely in 2027-2028.


Analysis · SGMT · Life Sciences

A major regulatory milestone has been reached: Sagimet Biosciences received FDA clearance to begin a Phase 3 clinical trial of denifanstat for moderate to severe acne. This de-risks the acne program and validates the company's strategic pivot toward dermatology. The trial is expected to start in H2 2026, and positive results could open a large commercial market. With $257.6 million in cash, the company has runway through the trial.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SGMT was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $574.5M. The 52-week trading range was $4.50 to $10.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SGMT - Latest Insights

SGMT
Oct 01, 2026, 5:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $9.03 info
Change: -$0.210 (-2%) info
Market Cap: $641.511M info
SGMT
Sep 30, 2026, 6:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $9.03 info
Change: -$1.00 (-10%) info
Market Cap: $641.511M info
SGMT
Sep 30, 2026, 5:53 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $9.03 info
Change: -$1.00 (-10%) info
Market Cap: $641.511M info
SGMT
Sep 30, 2026, 6:19 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.99
Real-time Price: $9.03 info
Change: -$0.960 (-10%) info
Market Cap: $641.511M info
SGMT
Sep 30, 2026, 6:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.43
Real-time Price: $9.03 info
Change: -$0.400 (-4%) info
Market Cap: $641.511M info